MARKET

LRMR

LRMR

Larimar Therapeutics Inc
NASDAQ
7.87
-0.12
-1.50%
After Hours: 7.66 -0.21 -2.67% 19:27 06/18 EDT
OPEN
7.98
PREV CLOSE
7.99
HIGH
8.30
LOW
7.83
VOLUME
450.84K
TURNOVER
0
52 WEEK HIGH
13.68
52 WEEK LOW
2.180
MARKET CAP
502.12M
P/E (TTM)
-8.1419
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LRMR last week (0610-0614)?
Weekly Report · 1d ago
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Shares of AMC Networks Inc. (NASDAQ:AMCX) fell sharply in today's pre-market trading. The company announced a private offering of $125 million of convertible senior notes. The Dow futures fell around 50 points on Monday. U.S. Stock futures were mixed in the morning trading session.
Benzinga · 1d ago
Weekly Report: what happened at LRMR last week (0603-0607)?
Weekly Report · 06/10 11:57
Moderna mRNA candidate chosen for FDA rare disease therapy acceleration program
Moderna's mRNA candidate chosen for FDA rare disease therapy acceleration program. The U.S. FDA has selected Moderna's therapeutic mRNA-3705 for methylmalonic acidemia. The program is designed to accelerate development of rare disease drugs. Larimar Therapeutics' candidate for Friedreich's ataxia also selected.
Seeking Alpha · 06/06 14:13
Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Larimar Therapeutics (LRMR)
TipRanks · 06/04 08:40
Weekly Report: what happened at LRMR last week (0527-0531)?
Weekly Report · 06/03 12:00
Larimar Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 05/31 21:37
Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
Seeking Alpha · 05/31 20:11
More
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Webull offers Larimar Therapeutics Inc stock information, including NASDAQ: LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.